The indenoisoquinoline analogue 9 of nitidine (1) has been prepared and found to possess significant anticancer activity against L1210 lymphoid leukemia, P388 lymphocytic leukemia, and B16 melanocarcinoma. Analogue 14, which lacks the B ring of nitidine (1), has also been synthesized. Compound 14 retains the in vitro toxicity associated with nitidine (1) but is devoid of antileukemic activity. The
已制备了可尼替丁(1)的
茚并
异喹啉类似物9,发现对L1210淋巴白血病,P388淋巴细胞白血病和B16黑素瘤具有显着的抗癌活性。还合成了缺少亚
硝胺(1)B环的类似物14。化合物14保留了与亚
硝胺(1)有关的体外毒性,但没有抗白血病活性。讨论了可能导致两个密切相关的类似物9和14之间
生物学活性差异的结构因素。